Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.69 |
| ▸ | FNTB | P49356 | 16/20 | 0.69 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926512 | 0.94 | FNTA (0.72) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6928267 | 0.93 | FNTA (0.70) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6925962 | 0.92 | FNTA (0.70) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6925574 | 0.91 | FNTA (0.66) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6599415 | 0.91 | FNTA (0.69) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6927052 | 0.89 | FNTA (0.67) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6972800 | 0.88 | FNTA (0.68) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6924592 | 0.88 | FNTA (0.66) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6599326 | 0.88 | FNTA (0.66) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6978951 | 0.88 | FNTA (0.69) | FNTAFNTBPGGT1BCYP3A4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | claimed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | claimed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
| EP-1045846-A1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LIMITED (KR) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999028315-A1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD. (KR) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | FNTA 1/4885FNTB 2/4885PGGT1B 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.